Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
Open Access
- 1 June 2025
- journal article
- case report
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 1453-1457
Abstract
This article reports a 59-year-old female patient who was diagnosed with segmental hyaline vasculitis and treated with tofacitinib for 2 months. In this case, multiple dark purplish-red spots were seen on both lower limbs, which did not fade with pressure. Flaky dark red spots, petechiae, ulcers, and necrosis were seen on the ankles. Histopathological manifestations were consistent with segmental hyaline vasculitis. The lesions subsided after the patient was treated with oral tofacitinib 5 mg twice daily for 1 month.Keywords
This publication has 17 references indexed in Scilit:
- Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping ReviewClinical, Cosmetic and Investigational Dermatology, 2024
- Increased Janus kinase activation in cutaneous vasculitisJournal of the American Academy of Dermatology, 2023
- Peripheral neuropathy and livedoid vasculopathyJournal of Neurology, 2022
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid ArthritisNew England Journal of Medicine, 2022
- Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic DiseaseEndocrine Reviews, 2021
- Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinibDermatologic Therapy, 2020
- Livedoid vasculopathy: how to diagnose and how to treat?Journal of the European Academy of Dermatology and Venereology, 2019
- Therapeutic effect of autologous platelet-rich plasma (PRP) on recalcitrant cutaneous ulcers in livedoid vasculopathyJAAD Case Reports, 2015
- Livedoid vasculopathy: thrombotic or inflammatory disease?Clinical and Experimental Dermatology, 2010
- Livedo vasculitis. Segmental hyalinizing vasculitis of the dermisArchives of Dermatology, 1967